Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "drug"

4425 News Found

Thermo Fisher launches genetic test to personalize transplant drug dosing
Technology | February 28, 2026

Thermo Fisher launches genetic test to personalize transplant drug dosing

The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus


Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
News | February 25, 2026

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery


UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
News | February 25, 2026

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis

NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production


UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction
News | February 24, 2026

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences


Novo Nordisk’s
Clinical Trials | February 24, 2026

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies


VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
News | February 23, 2026

VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities


BioVersys’ novel TB drug shows promising results in Phase 2a Trial
Clinical Trials | February 23, 2026

BioVersys’ novel TB drug shows promising results in Phase 2a Trial

The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project


FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer
Drug Approval | February 21, 2026

FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer

The NDA filing is supported by results from the phase III evERA Breast Cancer study